Document is current
Any future updates will be listed below
-
Authors
Cuesta-Mateos, Carlos http://orcid.org/0000-0002-1576-9790
Fuentes, Patricia
Schrader, Alexandra
Juárez-Sánchez, Raquel
Loscertales, Javier
Mateu-Albero, Tamara
Vega-Piris, Lorena
Espartero-Santos, Marina
Marcos-Jimenez, Ana
Sánchez-López, Blanca Andrea
Pérez-García, Yaiza
Jungherz, Dennis
Oberbeck, Sebastian
Wahnschaffe, Linus
Kreutzman, Anna
Andersson, Emma I.
Mustjoki, Satu
Faber, Edgar
Urzainqui, Ana
Fresno, Manuel
Stamatakis, Kostantino
Alfranca, Arantzazu
Terrón, Fernando
Herling, Marco
Toribio, María Luisa
Muñoz-Calleja, Cecilia
-
Funding
Funding for this research was provided by:
Ministerio de Sanidad y Consumo de España (PI015/02085, PI18/01163)
Ministerio de Economía y Competitividad de España (RTC-2015-3318-1, RTC-2015-3318-1)
German Research Foundation (DFG; HE3553/4-2)
José Carreras Leukämie-Stiftung ((03F/2016))
Fritz Thyssen Stiftung ((10.15.2.034MN))
Agencia Estatal de Investigación (SAF2016-75442-R)
- License Information
-
More Information
Article History
Received: 5 September 2020
Accepted: 12 October 2020
First Online: 24 October 2020
Ethics approval and consent to participate
: The clinical study was performed in accordance with the principles of the Declaration of Helsinki and was approved and supervised by the Ethics Committee of Hospital Universitario de la Princesa (PI-352). Written informed consent was obtained from each patient before they entered the study. All animal procedures were carried out at CBM-SO (Madrid, Spain) in accordance with the guidelines approved by the Animal Experimentation Ethics Committee of the Spanish National Research Council.
: Not applicable.
: CCM declares that he is an employee of Immunological and Medical Products (IMMED S.L.), Madrid, Spain. FT declares that he is CEO and a shareholder in the same company. CMC is consultant of IMMED S.L., has a granted patent for the use of therapeutic antibodies targeting CCR7 in cancer and has received research funds from IMMED.S.L. SM has received honoraria and research funding from BMS, Novartis and Pfizer (not related to this study). EF has received honoraria and research funding from Angelini, BMS, Novartis and Terumo BCT (not related to this study). The other authors declare that they have no potential competing interests.
